TradeTrade
Jump to any asset 844 assets, updated daily

ResMed Inc. (RMD)

ResMed Inc. NYSE

$234.17 -0.8750 (-0.37%)
Latest Price
AI Analyst Consensus
Hold
58 / 100
ResMed Inc. (RMD) is trading at $234.165, showing strong technical indicators with its price above key moving averages and a bullish 14-day RSI. The company has a history of beating EPS estimates, most recently by 2.08% in August 2026, and maintains a healthy profit margin of 26.95% against a sector average of 6.9% ROE. However, the stock faces moderate selling pressure from insiders, with $40.8 million in sales across recent filings, and the median analyst price target of $240.00 offers only a 2.5% upside from the current price. The company's revenue growth of 8.6% slightly outpaces the sector median of 8.1%, and its debt-to-equity ratio of 0.13 is well within industry norms. Despite these fundamental strengths, the limited analyst upside and insider selling warrant a cautious approach, suggesting that the stock may be fairly valued at current levels.

RMD at a glance

ResMed Inc. (RMD): Hold, 58/100 on CleaRank's AI score.

  • Trend Up: the price is above both its 50- and 200-day moving averages ($226.28 and $225.05).
  • Earnings RMD beat estimates in 4 of its last 4 quarters, yet fell the next day after 3 of those beats.
  • Insiders Insiders sold $40.8M and made no open-market purchases over the last 18 months.
  • Valuation P/E of 22.5 against 31.9 for the Healthcare sector: a discount to peers (-29%).

As of October 14, 2026, ResMed Inc. (RMD) trades at $234.17. Wall Street's consensus target is $240.00 across 20 analysts. The 14-day RSI (daily closes) is 64, showing bullish momentum without being overbought, and the price is above its 50-day simple moving average of $226.28.

Figures as of October 14, 2026.

Only on CleaRank

Figures we compute ourselves from RMD's own price, earnings and insider-filing history. Tap one to see it in context.

RMD Price Analysis

Market Metrics

Open
$235.00
Day Range
$232.89 to $236.75
Prev Close
$235.04
Volume
43.6K
52-Week Range
$180.27 to $277.67
Market Cap
$33.06B

Peer Benchmarking

Valuation vs Sector (Healthcare)

Performance vs XLV

Sector Position Analysis
Trading at a notable discount to sector peers (-29%), which may indicate undervaluation or specific company headwinds.

RMD Financial Performance

Revenue vs. Earnings

Annual

Quarterly

Earnings Reality Check

In the last 4 quarters, RMD beat the analyst estimate 4 times; the stock fell in the first session after 3 of those beats.
RMD earnings surprises and the stock's reaction
Report EPS estimate EPS actual Surprise First session 5 sessions
Aug 6, 2026 $2.89 $2.95 +2.08% -5.06% +1.57%
Apr 30, 2026 $2.80 $2.86 +2.14% -4.11% -3.24%
Jan 29, 2026 $2.72 $2.81 +3.31% +0.27% +3.66%
Oct 30, 2025 $2.50 $2.55 +2.00% -2.13% -1.03%

The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.

As of October 14, 2026, RMD has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on August 6, 2026, came in 2.08% above the estimate and the stock moved -5.06% in the first session.

RMD Analysis

Company's Health 4/5
12-Month Analyst Target +2.49% above price
Median of 20 analysts (12-month)
$240.00
AI Analyst Consensus Score Hold
ResMed Inc. (RMD) is trading above its 50-day SMA of $226.28 and its 200-day SMA of $225.05, indicating a positive short-to-medium term trend. The 14-day RSI is at 64.33, signaling bullish momentum without being overbought. The 20-day EMA at $226.86 also sits below the current price, reinforcing the upward trajectory. Key support levels are near the 50-day and 200-day SMAs, while resistance may be found near previous highs. The overall chart structure points to continued upward potential, but the lack of significant volume could limit immediate gains.
ProTips
  • Consider the implications of moderate insider selling totaling $40.8 million when sizing positions in RMD.
  • The stock is trading above its 50-day and 200-day moving averages ($226.28 and $225.05), indicating positive technical momentum, but watch for volume confirmation on any upward moves.
  • With a dividend yield of 1.05%, RMD may appeal to income-focused investors, but the limited upside to analyst targets suggests it may be more of a hold than a strong buy for capital appreciation.
Key Catalysts
Bearish Moderate Insider Selling

Insiders have sold a total of $40.8 million in stock across recent filings, indicating potential concerns or diversification strategies among management.

Source: Insider Trading Data
Neutral Consistent EPS Beats

ResMed Inc. has a track record of exceeding analyst EPS estimates, most recently by 2.08% in August 2026, which supports its fundamental valuation.

Source: Earnings Reports
Bullish Strong Technical Momentum

The stock is trading above its 50-day and 200-day moving averages ($226.28 and $225.05) with a bullish RSI, indicating positive price action and potential for further gains.

Source: Technical Analysis Data
Market Outlook
The company's strong profitability and healthy balance sheet provide a solid foundation, and the bullish technical momentum could support the stock price. However, the thesis could be altered by stronger-than-expected revenue growth, which is currently projected to be around 3.00% for the current year. Conversely, increased insider selling or a broader market downturn could pressure the stock, especially given the limited room for upside to current analyst targets.

Key Statistics

Market Cap 33.06B
P/E Ratio 22.53
EPS (TTM) 10.43
Dividend Yield 1.05%
52 Week High 277.67
52 Week Low 180.27

As of October 14, 2026, RMD trades at $234.17, with a market value of $33.06B, a P/E ratio of 22.53 and a dividend yield of 1.05%.

ResMed Inc. (RMD) exhibits a Price-to-Earnings ratio of 22.53, which is below the sector median P/E of 31.9, suggesting a potential valuation discount relative to peers. The company's profit margin stands at a strong 26.95%, significantly higher than the sector average ROE of 6.9%. Its Price-to-Sales ratio is 5.85, which is higher than the sector median PS of 3.7, indicating that investors are paying a premium for its sales. The company's debt-to-equity ratio of 0.13 is very low, indicating a strong balance sheet with minimal leverage. While the P/E ratio suggests value, the higher PS ratio warrants attention. The consistent profitability and strong balance sheet provide a solid foundation, but the market may be pricing in future growth at a premium.

Earnings & Growth Analysis

ResMed Inc. (RMD) most recently reported earnings on August 6, 2026, beating the analyst EPS estimate of $2.89 by 2.08% with an actual EPS of $2.95. This follows a pattern of consistent EPS beats, with the company exceeding estimates in all reported quarters. Revenue growth for the next quarter is projected at +2.00% year-over-year, with current year revenue growth estimated at +3.00%.

Key Risks

Moderate insider selling, totaling $40.8 million, presents a potential risk, indicating a lack of strong conviction from management. The limited analyst upside to the median price target of $240.00 suggests that the stock may be nearing its fair valuation, capping significant near-term gains. Also, the company's revenue growth is projected to slow to 3.00% for the current year, which could temper investor enthusiasm if not met.

Technical Indicators i

RSI (14-day) 64.33
MACD (12, 26) 2.21
SMA (50-day) 226.28
SMA (200-day) 225.05
Technical Rating Bullish
RSI
Bullish
SMA Cross
Neutral
Price vs SMA
Bullish
MACD
Bullish
Price action is firmly bullish above key moving averages.

As of October 14, 2026, with RMD at $234.17, its 14-day RSI is 64.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $226.28 and its 200-day is $225.05.

Calculated by CleaRank on daily closes as of October 14, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).

Market Correlations

How this stock moves relative to other assets

Based on 1 year of daily price data. Correlations may vary over different time periods.

S&P 500 (SPY) +0.34
Weak correlation
Nasdaq 100 (QQQ) +0.23
Weak correlation
Bitcoin (BTC) +0.08
Weak correlation
Gold (XAU) +0.14
Weak correlation

As of October 14, 2026, RMD's 1-year correlation of daily returns is +0.34 with S&P 500 (SPY), +0.23 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.14 with gold (XAU).

Check Custom Correlation

How does any other asset move with RMD? One year of daily closes, Pearson correlation.

Try

RMD Wall Street View

12-month price targets

Low $175.00 Median $240.00 (+2.5%) High $320.00

Ratings

Buy 9 Hold 10 Sell 1 3 months ago: 7 of 18 buy

Recent rating actions

Recent analyst rating actions on RMD
Date Firm Action Rating
Sep 15, 2026 RBC Capital Upgrade Outperform
Aug 31, 2026 Keybanc Maintains Overweight
Aug 19, 2026 Rothschild & Co Initiates Neutral
Aug 7, 2026 RBC Capital Maintains Sector Perform
Aug 7, 2026 Piper Sandler Maintains Neutral
Aug 7, 2026 Keybanc Maintains Overweight

As of October 14, 2026, 20 Wall Street analysts cover RMD: 9 rate it a buy or strong buy, 10 a hold and 1 a sell or strong sell. Their 12-month price targets range from $175.00 to $320.00, with a median of $240.00, 2.5% above the price of $234.17.

Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.

RMD Trade Plans

Specific entry, exit, and risk management levels

Select Your Trade Bias
Risk Tolerance
Conservative 2% Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →

Entry Strategies pick an entry style

Conservative
$231.82
Slight discount to current
Wait for small dip
Aggressive
$234.17
At current price
Enter now if confident

Risk Management

STOP LOSS
$224.87
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (64.3) and current market volatility

Profit Targets (Based on Conservative Entry)

TARGET 1
$238.78
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$243.41
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$250.37
+8% (Conservative)
+6.9% (Aggressive)

These levels come from RMD's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.

Growth of $10,000

A $10,000 investment in RMD in October 2016 would be worth about $36,356 today, compared with about $36,506 for the same investment in the S&P 500 benchmark. This is price change only; dividends paid along the way would add to it.

Compare with Another Ticker

RMD Drawdowns & Recovery

Worst fall, last 10 years
-54.5%
September 2021 to October 2023
Recovery
Not yet
still 20.8% below the September 2021 peak
From the 10-year high
-20.8%
highest close, September 2021
1-year holds that gained
72%
of every 1-year window

As of October 14, 2026, RMD's worst peak-to-trough fall over the last 10 years was -54.5% (September 2021 to October 2023); it is still 20.8% below that peak, and 72% of 1-year holding periods ended with a gain.

From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.

Monte Carlo Projection (10yr)

CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RMD today could grow to about $23,501 by 2036 in the base case, with a 90th-percentile outcome near $86,247 and a 10th-percentile outcome around $6,403. The simulation models price only; at today's 1.05% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.

RMD Stock Price Prediction: 2030

CleaRank's simulation projects a price near $330 for RMD by 2030 in the base case, from $234 today (1.4x over 4 years). The 10th-percentile path ends near $145. These are outcomes of a Monte Carlo simulation run on RMD's historical return distribution, not price targets, and they assume no dividends are reinvested.

RMD simulated price paths by year
Year 10th percentile Base case 90th percentile
2027 $169 $255 $385
2028 $155 $278 $497
2029 $148 $303 $617
2030 $145 $330 $750
2031 $143 $359 $900

Method: a lognormal simulation of RMD's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.

People Also Watch

RMD Insider Trading Analysis

Source: TwelveData, from SEC Form 4 filings
▲ Bought
None
No open-market buys
▼ Sold
$40.8M
50 Transactions
● Insiders
16
Active Traders
$ Avg Transaction
$816.3K
Moderate size

As of October 14, 2026, RMD insiders reported 50 open-market sales worth $40.8M and no open-market purchases over the last 18 months; grants and option exercises are not counted.

Recent insider transactions in RMD
Date Insider Type Shares Value
Oct 7, 2026
FARRELL MICHAEL J.
Chief Executive Officer
Sell 5.0K $1.1M
Oct 7, 2026
FARRELL MICHAEL J.
Chief Executive Officer
Option 5.0K $730.4K
Sep 8, 2026
FARRELL MICHAEL J
Chief Executive Officer
Sell 5.0K $1.1M
Sep 8, 2026
FARRELL MICHAEL J
Chief Executive Officer
Option 5.0K $730.4K
Aug 14, 2026
BLOOMER AARON
Chief Financial Officer
Grant 9.1K -
Aug 14, 2026
LEONG JUSTIN
Officer
Grant 6.5K -
Aug 7, 2026
FARRELL MICHAEL J
Chief Executive Officer
Sell 5.0K $1.0M
Aug 7, 2026
FARRELL MICHAEL J
Chief Executive Officer
Option 5.0K $730.4K
Aug 5, 2026
FARRELL PETER CRAIG
Director
Sell 8.0K $1.8M
Jun 8, 2026
FARRELL MICHAEL J
Chief Executive Officer
Sell 5.0K $968.1K

Frequently Asked Questions

How are ResMed Inc.'s (RMD) recent earnings?
ResMed Inc. (RMD) most recently reported earnings on August 6, 2026, exceeding analyst expectations by 2.08% with an EPS of $2.95 against an estimate of $2.89. This continues a trend of consistent earnings beats.
What is ResMed Inc.'s (RMD) dividend yield?
ResMed Inc. (RMD) offers a dividend yield of approximately 1.05%, with a dividend rate of $2.46.
What are the main risks facing ResMed Inc. (RMD)?
Key risks for ResMed Inc. (RMD) include moderate insider selling totaling $40.8 million, limited upside to the median analyst price target of $240.00, and a projected slowdown in revenue growth to 3.00% for the current year.
How does ResMed Inc. (RMD) compare to its sector peers?
ResMed Inc. (RMD) has a lower P/E ratio (22.53) than the sector median (31.9) but a higher Price-to-Sales ratio (5.85 vs 3.7). Its revenue growth (8.6%) slightly exceeds the sector median (8.1%), and its ROE (24.27%) is substantially higher than the sector average (6.9%).
What is the outlook for ResMed Inc. (RMD) options trading?
Given the stock's bullish momentum and moderate insider selling, options traders might consider strategies that account for potential limited upside. Analyzing implied volatility and the upcoming earnings estimates for December 2026 could inform decisions on call or put option strategies, balancing the risk of limited price appreciation against potential downside.
Is RMD in an uptrend?
Yes. ResMed Inc. (RMD) trades at $234.17, above both its 50- and 200-day moving averages ($226.28 and $225.05). Its 14-day RSI on daily closes is 64.3, showing bullish momentum without being overbought.
Are insiders buying or selling RMD?
Selling, on balance. In the last 18 months, RMD's officers, directors and large holders reported 50 sales worth $40.8M and 0 open-market purchases worth $0. Grants and option exercises are not counted as buying.
What is the analyst price target for RMD?
As of October 14, 2026, the 20 Wall Street analysts covering RMD have 12-month targets from $175.00 to $320.00, with a median of $240.00, 2.5% above the current price of $234.17. 9 rate it a buy or strong buy, 10 a hold and 1 a sell or strong sell. Three months ago 7 of 18 rated it a buy.
What is RMD's biggest drop in the last 10 years?
ResMed Inc. (RMD)'s worst peak-to-trough fall over the last 10 years was -54.5%, from September 2021 to October 2023. It has not regained that peak yet and is still 20.8% below it. Over the same period, 72% of 1-year holding periods ended with a gain.
What are RMD's best and worst months?
Over the last 10 years, July has been RMD's strongest month on average (+7.25%, rising in 10 of 10 years) and March its weakest (-3.07%, rising in 5 of 10 years). Seasonal averages describe the past and do not predict a given year.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The stock analysis, trade plans, and AI-generated signals presented for RMD are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All trade setups and performance metrics shown are hypothetical, hindsight-based, and simulated. They do not represent actual trades made by CleaRank or its affiliates. Stock prices can be volatile and are subject to market, economic, and company-specific risks. Market data is provided "as-is" and may be delayed by 15 minutes or more. We do not guarantee the accuracy, completeness, or timeliness of any data. You should never invest money you cannot afford to lose. Past performance does not guarantee future results. Consult a qualified financial advisor before making any investment decisions. Analysis generated on October 15, 2026.

Disclaimer:

Engaging in financial markets carries significant risk of total capital loss. Markets are volatile, unpredictable, and past success does not guarantee future results. Never invest funds you cannot afford to lose. CleaRank does not offer financial, investment, or advisory services. We provide no recommendations, endorsements, or guarantees regarding market outcomes. You alone are responsible for your decisions.

Advertiser Disclosure:

At CleaRank, clarity and transparency are more than ideals, they are the core of our operations. CleaRank is a paid SaaS platform: the Pro and Ultra workbench plans are paid subscriptions, while everything else on this site, including our trading calculators, tools and market news, is free to use. In the spirit of full disclosure: some of our free editorial content contains partner links, and we may earn affiliate commissions from them. This never affects what you pay. Please keep in mind that your confidence in our platform is what matters to us most and we are devoted to earning your trust every day through consistent transparency. CleaRank's Editorial team works independently from partner relationships and financial incentives. All material and information made available by CleaRank stem from our unique technology and methodology which are created to prioritize your needs as a trader and deliver actionable insights to help you make clearer decisions.